ATE547118T1 - Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung - Google Patents

Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung

Info

Publication number
ATE547118T1
ATE547118T1 AT08803235T AT08803235T ATE547118T1 AT E547118 T1 ATE547118 T1 AT E547118T1 AT 08803235 T AT08803235 T AT 08803235T AT 08803235 T AT08803235 T AT 08803235T AT E547118 T1 ATE547118 T1 AT E547118T1
Authority
AT
Austria
Prior art keywords
cyhv
khv
carpio
koi
herpes virus
Prior art date
Application number
AT08803235T
Other languages
English (en)
Inventor
Berenice Costes
Francois Lieffrig
Alain Vanderplasschen
Original Assignee
Univ Liege
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07115093A external-priority patent/EP2031065A1/de
Application filed by Univ Liege filed Critical Univ Liege
Application granted granted Critical
Publication of ATE547118T1 publication Critical patent/ATE547118T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16061—Methods of inactivation or attenuation
    • C12N2710/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT08803235T 2007-08-28 2008-08-26 Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung ATE547118T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07115093A EP2031065A1 (de) 2007-08-28 2007-08-28 Rekombinanter Koi-Herpesvirus (KHV) oder Cyprinid-Herpesvirus 3 (CyHV-3) und Impfstoff zur Prävention einer von KHV/CyHV-3 bei Cyprinus carpio carpio oder Cyprinus carpio (Koi) verursachten Erkrankung
EP07120939 2007-11-16
PCT/EP2008/061168 WO2009027412A1 (en) 2007-08-28 2008-08-26 A recombinant koi herpesvirus (khv) or cyprinid herpesvirus 3 (cyhv-3) and a vaccine for the prevention of a disease caused by khv/cyhv-3 in cyprinus carpio carpio or cyprinus carpio koi

Publications (1)

Publication Number Publication Date
ATE547118T1 true ATE547118T1 (de) 2012-03-15

Family

ID=40020044

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08803235T ATE547118T1 (de) 2007-08-28 2008-08-26 Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung

Country Status (12)

Country Link
US (1) US20110287050A1 (de)
EP (1) EP2195021B1 (de)
JP (1) JP2010536394A (de)
CN (1) CN101820905A (de)
AT (1) ATE547118T1 (de)
BR (1) BRPI0816134A2 (de)
MD (1) MD20100029A2 (de)
MX (1) MX2010002122A (de)
RS (1) RS20100059A (de)
RU (1) RU2010111725A (de)
TW (1) TW200924792A (de)
WO (1) WO2009027412A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112316113A (zh) * 2018-11-05 2021-02-05 共鳞实业(深圳)有限公司 用于预防或治疗鱼类感染CyHV-2的试剂及应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2010113988A1 (ja) * 2009-03-31 2012-10-11 国立大学法人三重大学 抗ｇｐｃｒ抗体の製造方法および抗ｇｐｃｒ抗体
EP2487241A1 (de) 2011-02-09 2012-08-15 Westfälische Wilhelms-Universität Münster RNAi-Agenzien und -Zusammensetzungen, die als Therapeutika für Karpfen von Nutzen sind
UA114719C2 (uk) * 2011-12-30 2017-07-25 Гесваль С.А. Рекомбінантний герпесвірус кої (khv) і вакцина для профілактики захворювання, що викликається khv
CN102973951A (zh) * 2012-11-26 2013-03-20 吉林农业大学 一种锦鲤疱疹病毒orf25核酸疫苗
CN104031143A (zh) * 2013-07-02 2014-09-10 广东省农业科学院动物卫生研究所 一种抗鲤科疱疹病毒3型鸡卵黄抗体及其制备方法和应用
AU2016217906B2 (en) * 2015-02-11 2021-09-02 Alma Mater Studiorum Universita' Di Bologna Retargeted herpesvirus with a glycoprotein H fusion
CN105755014B (zh) * 2016-03-23 2019-03-19 中国科学院水生生物研究所 CaHV-TNFR特异基因及应用
CN106834352B (zh) * 2017-02-27 2020-06-16 苏州大学 基于杆状病毒表达系统制备包裹鲤疱疹病毒ii型抗原的多角体的方法
CN109294974B (zh) * 2018-10-22 2022-09-13 浙江省淡水水产研究所 一种异育银鲫脊髓组织细胞系及其构建方法与其应用
CN110423714B (zh) * 2019-08-19 2020-11-06 中国水产科学研究院长江水产研究所 一种乳酸菌复合菌剂及其在抗鲤疱疹病毒ii型中的应用
CN113068640A (zh) * 2021-03-19 2021-07-06 北京市水产科学研究所（国家淡水渔业工程技术研究中心） 一种红色皮肤高覆盖率锦鲤品系的选育方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0382271B1 (de) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocole als Impfstoffadjuvans
JPH09267A (ja) * 1995-06-23 1997-01-07 Kyoritsu Shoji Kk チミジンキナーゼ遺伝子に変異を有する組換えネコヘルペスウイルス１型及びそれを含むワクチン
PT1140152E (pt) 1998-12-21 2003-11-28 Akzo Nobel Nv Metodo para producao de vacinas inactivadas adjuvadas com uma emulsao a/o
IL153775A0 (en) 2003-01-01 2003-07-31 Yissum Res Dev Co Immunizing fish against viral infection

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112316113A (zh) * 2018-11-05 2021-02-05 共鳞实业(深圳)有限公司 用于预防或治疗鱼类感染CyHV-2的试剂及应用

Also Published As

Publication number Publication date
CN101820905A (zh) 2010-09-01
EP2195021B1 (de) 2012-02-29
MD20100029A (ro) 2010-08-31
US20110287050A1 (en) 2011-11-24
BRPI0816134A2 (pt) 2015-07-28
JP2010536394A (ja) 2010-12-02
RU2010111725A (ru) 2011-10-10
RS20100059A (sr) 2011-06-30
MX2010002122A (es) 2010-07-06
WO2009027412A1 (en) 2009-03-05
TW200924792A (en) 2009-06-16
MD20100029A2 (ro) 2010-08-31
EP2195021A1 (de) 2010-06-16

Similar Documents

Publication Publication Date Title
ATE547118T1 (de) Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung
CO6361950A2 (es) Composiciones, vacunas y metodos del virus del herpes del ganado bovino -1
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
MX2012001882A (es) Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
EA201070794A1 (ru) Рекомбинантные антигены rsv
AR056566A1 (es) Vacunas y procedimientos para tratar la gripe canina
PL1881845T3 (pl) Szczepionki przeciwko wirusowi Nipah
EP2552490A4 (de) Ektodomänen des influenza-matrix-2-proteins, expressionssystem dafür und verwendungen davon
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
DE60330708D1 (de) Impfstoff gegen das west-nile-virus
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2017003117A (es) Particula tipo virus de flavivirus.
WO2007150008A3 (en) Polypeptides from african swine virus as vaccines for preventive and therapeutic use
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
AR065765A1 (es) Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias
MX363264B (es) Vectores de vacuna recombinante de herpesvirus bovino 1 (bohv-1) con baja virulencia.
MX391376B (es) Composiciones de la membrana de la cáscara del huevo para usarse en el tratamiento de la cadena ligera kappa del factor nuclear de las células b activadas (nf-kb) en un organismo hospedero.
AR040601A1 (es) Mutantes ehv negativos de gm sin elementos heterologos
IN2011KN02819A (de)
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor
TN2014000393A1 (en) Modified marek's disease virus, and vaccines made therefrom
AR048671A1 (es) Procedimiento de vacunacion contra la infeccion testicular por bvdv